ZNF207 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13322893	0.55	2/20
SCHEMBL1136867	0.33	2/20
SCHEMBL1136764	0.31	2/20
SCHEMBL12863986	0.31	2/20
Molibresib (SCHEMBL1872390)	1.00	1/20
Molibresib (SCHEMBL12671490)	1.00	1/20
Molibresib (SCHEMBL12966358)	1.00	1/20
SCHEMBL9998851	0.91	1/20
SCHEMBL14756282	0.88	1/20
SCHEMBL15980874	0.88	1/20
SCHEMBL12966165	0.87	1/20
SCHEMBL14756215	0.87	1/20
SCHEMBL14756339	0.87	1/20
SCHEMBL15980861	0.87	1/20
SCHEMBL9998825	0.86	1/20
SCHEMBL15980803	0.86	1/20
SCHEMBL1874116	0.85	1/20
SCHEMBL12671221	0.85	1/20
SCHEMBL14756021	0.85	1/20
SCHEMBL14756240	0.85	1/20

Clinical trials — most relevant to ZNF207 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
ZR-CHOP in DLBCL With Specific Gene Abnormality	PHASE2	UNKNOWN
SCARFREE-001: Verteporfin for Scar Prevention	PHASE2	NOT_YET_RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)	PHASE2	COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer	PHASE1	RECRUITING
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia	PHASE1	COMPLETED
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Chromosome 9 P Minus Syndrome	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma	nan	UNKNOWN
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)	nan	UNKNOWN
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer	nan	COMPLETED
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome	nan	COMPLETED
Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis	nan	RECRUITING
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)	nan	COMPLETED
Angiotensinogen Gene and Hypertension	nan	UNKNOWN
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors	nan	ACTIVE_NOT_RECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a ZNF207 binder may also engage these)

Protein	Name	Similarity
Q9JMD0	—	1.000	Q9JMD0 →
Q5R8K4	—	1.000	Q5R8K4 →
Q7ZXV8	—	1.000	Q7ZXV8 →
F6HQ26	—	0.988	F6HQ26 →
Q9C5G0	—	0.987	Q9C5G0 →
C5XZK6	—	0.986	C5XZK6 →
Q63627	—	0.985	Q63627 →
Q56XE4	—	0.984	Q56XE4 →
C5XYW4	—	0.983	C5XYW4 →
O95104	—	0.981	O95104 →
Q9Y2W2	—	0.981	Q9Y2W2 →
Q923D5	—	0.980	Q923D5 →
Q6P0D5	—	0.979	Q6P0D5 →
Q7TSH6	—	0.979	Q7TSH6 →
Q9LV14	—	0.979	Q9LV14 →
Q8CGF7	—	0.978	Q8CGF7 →
Q8VIJ6	—	0.978	Q8VIJ6 →
Q5PQQ2	—	0.978	Q5PQQ2 →
Q5KC16	—	0.978	Q5KC16 →
B3NGA1	—	0.978	B3NGA1 →
Q6DDW4	—	0.978	Q6DDW4 →
Q960X8	—	0.977	Q960X8 →
SFPQ	Splicing factor, proline- and glutamine-rich	0.977	landscape →
Q0P5D2	—	0.977	Q0P5D2 →
EP300	Histone acetyltransferase p300	0.977	landscape →
Q99KN9	—	0.977	Q99KN9 →
Q9Y149	—	0.977	Q9Y149 →
Q96RN5	—	0.977	Q96RN5 →
B4HUE4	—	0.977	B4HUE4 →
Q6NVF9	—	0.977	Q6NVF9 →